Skip to main content
Log in

Ossär metastasiertes kastrationsresistentes Prostatakarzinom

Kein Vorteil durch Addition von Radium-223 zu Abirateronacetat

  • journal club
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Ryan CJ et al. Lancet Oncol. 2015;16(2):152–60

    Article  CAS  Google Scholar 

  2. Parker C et al. N Engl J Med. 2013;369(3):213–23

    Article  CAS  Google Scholar 

  3. Saad F et al. Lancet Oncol. 2016;17(9):1306–16

    Article  CAS  Google Scholar 

  4. Smith M et al. Lancet Oncol. 2019;20(3):408–19

    Article  CAS  Google Scholar 

  5. Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittelrichtlinie (AM-RL). BAnz AT 16.11.2018 B5

Literatur

  • Smith M et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(3):408–19

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Andreas Schalhorn.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schalhorn, A. Kein Vorteil durch Addition von Radium-223 zu Abirateronacetat. Info Onkol. 22, 36–37 (2019). https://doi.org/10.1007/s15004-019-6556-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-019-6556-3

Navigation